Short Interest in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Declines By 23.8%
Short Interest in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Declines By 23.8%
Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Rating) was the target of a large decline in short interest in November. As of November 15th, there was short interest totalling 118,100 shares, a decline of 23.8% from the October 31st total of 154,900 shares. Approximately 1.2% of the company's stock are short sold. Based on an average trading volume of 78,300 shares, the days-to-cover ratio is presently 1.5 days.
BlueJay診斷公司(納斯達克代碼：BJDX-GET評級)是空頭股數11月份大幅下跌的目標。截至11月15日，空頭股數共有11.81萬股，較10月31日的15.49萬股減少23.8%。該公司約1.2%的股票被賣空。以平均成交量78,300股計算，目前天數與回補比率為1.5天。
Bluejay Diagnostics Trading Down 1.5 %
BlueJay診斷公司股價下跌1.5%
BJDX traded down $0.01 during trading on Friday, hitting $0.67. The company had a trading volume of 87,667 shares, compared to its average volume of 58,824. Bluejay Diagnostics has a one year low of $0.61 and a one year high of $3.59. The firm's 50-day moving average price is $0.78 and its 200 day moving average price is $0.98.
在週五的交易中，BJDX的交易價格下跌了0.01美元，觸及0.67美元。該公司的成交量為87,667股，而其平均成交量為58,824股。BlueJay Diagnostics的一年低點為0.61美元，一年高位為3.59美元。該公司的50日移動均線價格為0.78美元，200日移動均線價格為0.98美元。
Institutional Investors Weigh In On Bluejay Diagnostics
機構投資者參與Bluejay Diagnostics
Institutional investors have recently added to or reduced their stakes in the stock. Millennium Management LLC acquired a new stake in Bluejay Diagnostics in the 2nd quarter valued at $27,000. Virtu Financial LLC acquired a new stake in Bluejay Diagnostics in the 2nd quarter valued at $45,000. Finally, Renaissance Technologies LLC acquired a new stake in Bluejay Diagnostics in the 2nd quarter valued at $54,000. 1.21% of the stock is owned by institutional investors.
機構投資者最近增持或減持了該股。Millennium Management LLC在第二季度收購了Bluejay Diagnostics的新股份，價值2.7萬美元。Virtu Financial LLC在第二季度收購了Bluejay Diagnostics的新股份，價值4.5萬美元。最後，復興科技有限責任公司在第二季度收購了Bluejay Diagnostics的新股份，價值54,000美元。1.21%的股份由機構投資者持有。
Bluejay Diagnostics Company Profile
BlueJay診斷公司簡介
Bluejay Diagnostics, Inc, a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components.
BlueJay診斷公司是一家診斷公司，在美國開發和銷售用於分診、診斷和監測疾病進展的患者產品。它正在開發一個技術平臺，包括使用非接觸式離心力協調血液處理、生物標記物分離和免疫分析準備的SYMPHONY熒光免疫分析儀；以及包括試劑和組件的SYMPHONY卡片庫。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Bluejay Diagnostics (BJDX)
- Institutions Are Buying Ambarella, Should You?
- Can ZIM Defy Broad Downturn In The Container Shipping Industry?
- Ford Revving Up Production Of EV Power Units At U.K. Plant
- Are the Short Sellers Still Right About Mullen Automotive stock?
- La-Z-Boy Reclines To More Comfortable Levels
- 免費獲取StockNews.com關於Bluejay診斷的研究報告(BJDX)
- 機構正在購買安巴雷拉，你應該嗎？
- ZIM能否抵禦集裝箱航運業的普遍低迷？
- 福特在英國工廠加速生產電動汽車動力裝置
- 賣空者對馬倫汽車股票的看法仍然正確嗎？
- La-Z-Boy傾斜到更舒適的水平
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
接收Bluejay診斷日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收Bluejay Diagnostics和相關公司的最新新聞和分析師評級的每日摘要。